Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Clinical Trial of Recombinant RSV Vaccine (CHO Cell) (Adjuvanted) in Chinese Population Aged 18 Years and Older.

22 de maio de 2026 atualizado por: Ab&B Bio-tech Co., Ltd.JS

A Randomized, Blinded, Controlled Phase I/II Clinical Trial to Evaluate the Safety and Immunogenicity of a Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell) (Adjuvanted) in Adults Aged 18 Years and Older.

The primary objective of the phase I trial is to evaluate the safety and tolerability of different doses of the recombinant respiratory syncytial virus vaccine (CHO cell) (Adjuvanted) in adults aged 18 years and older, with the secondary objective being to assess its immunogenicity. The primary objectives of the phase II trial are to evaluate the immunogenicity and safety of the recombinant respiratory syncytial virus vaccine (CHO cell) (Adjuvanted) with different adjuvant ratios in adults aged 60 years and older, with the secondary objective being to evaluate the persistence of immune responses.

Visão geral do estudo

Tipo de estudo

Intervencional

Inscrição (Estimado)

470

Estágio

  • Fase 2
  • Fase 1

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

    • Sichuan
      • Zigong, Sichuan, China
        • Recrutamento
        • Zigong Center for Disease Control and Prevention
        • Contato:
        • Investigador principal:
          • Ting Huang, Bachelor

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Adulto
  • Adulto mais velho

Aceita Voluntários Saudáveis

Sim

Descrição

Inclusion Criteria:

  • Males or females aged 18 years and older at the time of enrollment (aged 18 years and older for the phase I part; aged 60 years and older for the phase II part), who are able to provide legal proof of identity.
  • Voluntarily agree to participate in the trial, able to fully understand and sign the informed consent form.
  • Able to attend all scheduled follow-up visits and comply with the requirements of the clinical trial protocol to complete the study.
  • Female participants must meet the following criteria: In the phase I part, women of childbearing potential* must have a negative pregnancy test prior to enrollment and be willing to use effective contraceptive measures for 12 months after receiving the investigational vaccine; in the phase II part, only women of non-childbearing potential will be enrolled.

    • Women of childbearing potential: Defined as females who have experienced menarche and have not yet entered menopause, unless permanently sterile, such as documented bilateral salpingectomy, bilateral oophorectomy, or hysterectomy; menopause is defined as amenorrhea for 12 consecutive months without other medical cause.

[Effective contraceptive measures include: oral contraceptives, injectable contraceptives, subdermal implants or hormonal patches, intrauterine device (IUD), sterilization surgery, abstinence (no sexual intercourse), male condoms, etc.; rhythm method, withdrawal, and emergency contraception are not considered effective contraceptive measures.]

  • Axillary body temperature ≤ 37.0°C measured on site prior to vaccination on the day of vaccination.

Exclusion Criteria:

  • Clinically significant laboratory abnormalities that, in the investigator's comprehensive judgment, preclude enrollment (applicable only to the phase I part).
  • Pregnant or breastfeeding women.
  • A clear diagnosis of RSV infection or a history of RSV infection-related respiratory disease within 6 months prior to vaccination.
  • Use of immunoglobulins or/and any blood products or plasma derivatives within 3 months prior to vaccination, or planned use during the study.
  • Treatment with immunomodulators (including immunosuppressants and immunostimulants) within 6 months prior to vaccination (e.g., long-term use of systemic glucocorticoids for ≥14 days at a dose of ≥2 mg/kg/day or ≥20 mg/day prednisone or equivalent) (excluding inhaled, intra-articular, and topical steroids).
  • Administration or planned use of long-acting immunomodulatory drugs (e.g., infliximab) at any time during the study.
  • A history of severe allergic reactions (e.g., anaphylactic shock, allergic laryngeal edema, Henoch-Schönlein purpura, thrombocytopenic purpura, Arthus reaction) following any previous vaccination or drug use, or a family history of severe allergies.
  • Impaired immune function or a diagnosis of congenital or acquired immunodeficiency, or human immunodeficiency virus (HIV) infection.
  • A personal or family history of convulsions, epilepsy, encephalopathy, psychiatric disorders, or neurological diseases (such as Guillain-Barré syndrome, Miller Fisher syndrome).
  • A diagnosis of lymphoproliferative disease or malignant tumor within 5 years.
  • Clinically significant electrocardiogram (ECG) abnormalities as determined by the investigator (applicable only to the phase I part).
  • Previous vaccination with any licensed or investigational RSV vaccine prior to enrollment, or planned vaccination during the study.
  • Receipt of any vaccine within 14 days prior to vaccination, or any live vaccine within 30 days prior to vaccination.
  • An acute disease or an acute exacerbation of a chronic disease within 3 days prior to vaccination, or use of antipyretic, analgesic, or anti-allergy medications.
  • Suspected or known alcohol abuse or alcohol dependence (referring to a drinking pattern that causes serious mental or physical health problems) or drug abuse.
  • A history of thrombocytopenia or other coagulation disorders that may contraindicate intramuscular injection.
  • Severe or unstable chronic diseases, including but not limited to cardiovascular diseases [e.g., hypertension uncontrolled by medication (on-site blood pressure measurement prior to vaccination: systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg), coronary heart disease, myocarditis, pericarditis, atrial fibrillation], metabolic diseases (e.g., poorly controlled diabetes), hematological disorders (e.g., severe anemia, hemophilia), hepatic or renal diseases, digestive system diseases, respiratory system diseases (e.g., chronic obstructive pulmonary disease, active pulmonary tuberculosis, other severe respiratory diseases).

Note: For participants aged 60 years and older, those with pre-existing stable disease may be enrolled. This is defined as participants who may have underlying conditions such as hypertension or diabetes, provided that symptoms and signs are stable and medically controllable as assessed by the investigator prior to vaccination, and who have not required changes to the treatment/medication regimen or hospitalization due to the underlying condition within 3 months.

  • A history of confirmed immune-mediated/autoimmune diseases (e.g., cold agglutinin hemolytic anemia, lymphadenopathy, eosinophilia, systemic lupus erythematosus, gout, hyperuricemia, acute disseminated encephalomyelitis, immune thrombocytopenia, autoimmune aplastic anemia, autoimmune neutropenia, autoimmune lymphoproliferative syndrome, thrombocytopenic purpura).
  • Asplenia or functional asplenia, as well as any condition resulting in asplenia or splenectomy.
  • Currently participating in or planning to participate in another clinical study involving investigational or unregistered products (drugs, vaccines, medical devices, etc.) during this study.
  • Any other condition that, in the investigator's judgment, makes the individual unsuitable for participation in this clinical trial.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Prevenção
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Quadruplicar

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Comparador de Placebo: Grupo Placebo
The vaccine is administered as a single 0.5 mL intramuscular injection into the deltoid muscle of the upper arm on Day 0.
Experimental: Investigational Vaccine 1 (Low Dose) Group
The vaccine is administered as a single 0.25 mL intramuscular injection into the deltoid muscle of the upper arm on Day 0.
Experimental: Investigational Vaccine 2 (Low Dose) Group
The vaccine is administered as a single 0.25 mL intramuscular injection into the deltoid muscle of the upper arm on Day 0.
The vaccine is administered as a single 0.5 mL intramuscular injection into the deltoid muscle of the upper arm on Day 0.
Experimental: Investigational Vaccine 1 Group
The vaccine is administered as a single 0.5 mL intramuscular injection into the deltoid muscle of the upper arm on Day 0.
Experimental: Investigational Vaccine 2 Group
The vaccine is administered as a single 0.25 mL intramuscular injection into the deltoid muscle of the upper arm on Day 0.
The vaccine is administered as a single 0.5 mL intramuscular injection into the deltoid muscle of the upper arm on Day 0.
Experimental: Investigational Vaccine 3 Group
The vaccine is administered as a single 0.5 mL intramuscular injection into the deltoid muscle of the upper arm on Day 0.
Comparador de Placebo: Adjuvant Control Group
The vaccine is administered as a single 0.5 mL intramuscular injection into the deltoid muscle of the upper arm on Day 0.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Incidence of solicited (local and systemic) adverse events (AEs) within 14 days post-vaccination.
Prazo: Within 14 days post-vaccination.
Within 14 days post-vaccination.
Incidence of unsolicited AEs within 30 days post-vaccination.
Prazo: Within 30 days post-vaccination.
Within 30 days post-vaccination.
Incidence of clinically significant laboratory abnormalities(blood biochemistry, blood routine, coagulation function, urinalysis) on Day 3 post-vaccination, and incidence of clinically significant ECG abnormalities on Days 3, 14, and 30 post-vaccination.
Prazo: On Days 3, 14, and 30 post-vaccination
Applicable to Phase I only
On Days 3, 14, and 30 post-vaccination
Incidence of serious adverse events (SAEs) and adverse events of special interest (AESIs) within 12 months post-vaccination.
Prazo: Within 12 months post-vaccination.
Within 12 months post-vaccination.
At 1 month post-vaccination: geometric mean titer (GMT) of neutralizing antibodies against RSV-A and RSV-B.
Prazo: At 1 month post-vaccination
Applicable to Phase Ⅱ only
At 1 month post-vaccination
At 1 month post-vaccination: seroresponse rate (SRR) of neutralizing antibodies against RSV-A and RSV-B.
Prazo: At 1 month post-vaccination
Applicable to Phase Ⅱ only
At 1 month post-vaccination
At 1 month post-vaccination: geometric mean fold rise (GMFR) of neutralizing antibodies against RSV-A and RSV-B.
Prazo: At 1 month post-vaccination
Applicable to Phase Ⅱ only
At 1 month post-vaccination
At 1 month post-vaccination: geometric mean concentration (GMC) of pre-F specific IgG antibodies against both RSV-A and RSV-B subtypes.
Prazo: At 1 month post-vaccination
Applicable to Phase Ⅱ only
At 1 month post-vaccination
At 1 month post-vaccination: SRR of pre-F specific IgG antibodies against both RSV-A and RSV-B subtypes.
Prazo: At 1 month post-vaccination
Applicable to Phase Ⅱ only
At 1 month post-vaccination
At 1 month post-vaccination: GMFR of pre-F specific IgG antibodies against both RSV-A and RSV-B subtypes.
Prazo: At 1 month post-vaccination
Applicable to Phase Ⅱ only
At 1 month post-vaccination

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
At 1 month post-vaccination: GMT of neutralizing antibodies against RSV-A and RSV-B.
Prazo: At 1 month post-vaccination
Applicable to Phase I only
At 1 month post-vaccination
At 1 month post-vaccination: SRR of neutralizing antibodies against RSV-A and RSV-B.
Prazo: At 1 month post-vaccination
Applicable to Phase I only
At 1 month post-vaccination
At 1 month post-vaccination: GMFR of neutralizing antibodies against RSV-A and RSV-B.
Prazo: At 1 month post-vaccination
Applicable to Phase I only
At 1 month post-vaccination
At 1 month post-vaccination: GMC of pre-F specific IgG antibodies against both RSV-A and RSV-B subtypes.
Prazo: At 1 month post-vaccination
Applicable to Phase I only
At 1 month post-vaccination
At 1 month post-vaccination: SRR of pre-F specific IgG antibodies against both RSV-A and RSV-B subtypes.
Prazo: At 1 month post-vaccination
Applicable to Phase I only
At 1 month post-vaccination
At 1 month post-vaccination: GMFR of pre-F specific IgG antibodies against both RSV-A and RSV-B subtypes.
Prazo: At 1 month post-vaccination
Applicable to Phase I only
At 1 month post-vaccination
At 14 days, 6 months, 12 months, and 24 months post-vaccination: GMT of neutralizing antibodies against RSV-A and RSV-B.
Prazo: At 14 days, 6 months, 12 months, and 24 months post-vaccination
Applicable to Phase Ⅱ only
At 14 days, 6 months, 12 months, and 24 months post-vaccination
At 14 days, 6 months, 12 months, and 24 months post-vaccination: SRR of neutralizing antibodies against RSV-A and RSV-B.
Prazo: At 14 days, 6 months, 12 months, and 24 months post-vaccination
Applicable to Phase Ⅱ only
At 14 days, 6 months, 12 months, and 24 months post-vaccination
At 14 days, 6 months, 12 months, and 24 months post-vaccination: GMFR of neutralizing antibodies against RSV-A and RSV-B.
Prazo: At 14 days, 6 months, 12 months, and 24 months post-vaccination
Applicable to Phase Ⅱ only
At 14 days, 6 months, 12 months, and 24 months post-vaccination
At 14 days, 6 months, 12 months, and 24 months post-vaccination: GMC of pre-F specific IgG antibodies against both RSV-A and RSV-B subtypes.
Prazo: At 14 days, 6 months, 12 months, and 24 months post-vaccination
Applicable to Phase Ⅱ only
At 14 days, 6 months, 12 months, and 24 months post-vaccination
At 14 days, 6 months, 12 months, and 24 months post-vaccination: SRR of pre-F specific IgG antibodies against both RSV-A and RSV-B subtypes.
Prazo: At 14 days, 6 months, 12 months, and 24 months post-vaccination
Applicable to Phase Ⅱ only
At 14 days, 6 months, 12 months, and 24 months post-vaccination
At 14 days, 6 months, 12 months, and 24 months post-vaccination: GMFR of pre-F specific IgG antibodies against both RSV-A and RSV-B subtypes.
Prazo: At 14 days, 6 months, 12 months, and 24 months post-vaccination
Applicable to Phase Ⅱ only
At 14 days, 6 months, 12 months, and 24 months post-vaccination
At 14 days, 1 month, and 6 months post-vaccination: counts of CD4+ and CD8+ T cells expressing at least two activation markers (IFN-γ, IL-2, TNF-α, CD40L)
Prazo: At 14 days, 1 month, and 6 months post-vaccination
Applicable to Phase Ⅱ only
At 14 days, 1 month, and 6 months post-vaccination

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Colaboradores

Investigadores

  • Investigador principal: Ting Huang, Bachelor, Sichuan Center for Disease Control and Prevention

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

14 de maio de 2026

Conclusão Primária (Estimado)

14 de setembro de 2027

Conclusão do estudo (Estimado)

14 de agosto de 2029

Datas de inscrição no estudo

Enviado pela primeira vez

29 de abril de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

6 de maio de 2026

Primeira postagem (Real)

13 de maio de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

27 de maio de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

22 de maio de 2026

Última verificação

1 de maio de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever